On July 9, 2025, B of A Securities made significant changes to their price target for RxSight (RXST, Financial), setting the new target at $9.00. This represents a dramatic 50% reduction from the previous price target of $18.00.
Despite the adjustment in the price target, the analyst Craig Bijou maintained an "Underperform" rating for RxSight (RXST, Financial). The "Underperform" rating remains consistent with the previous evaluation, indicating the potential for the company to perform below the sector average.
These changes come amid a period of reevaluation by financial analysts, necessitated by emerging market conditions and company performance metrics. The new price target and maintained rating underscore the cautious approach analysts are adopting with RxSight (RXST, Financial).
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for RxSight Inc (RXST, Financial) is $18.30 with a high estimate of $28.00 and a low estimate of $9.00. The average target implies an upside of 133.27% from the current price of $7.85. More detailed estimate data can be found on the RxSight Inc (RXST) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, RxSight Inc's (RXST, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for RxSight Inc (RXST, Financial) in one year is $59.29, suggesting a upside of 655.77% from the current price of $7.845. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the RxSight Inc (RXST) Summary page.
